TORONTO, July 28, 2015 /CNW/ - Syncordia
Technologies and Healthcare Solutions, Corp. (TSXV: SYN)
("Syncordia" or the "Company") today reported financial results for
the twelve months ended March 31,
2015.
Reported results reflect five months of operations of Health
Services Integration Inc. ("HSI"), which was acquired effective
October 31, 2014. Syncordia had no
operational activities for the period ended March 31, 2014. All results are reported in US
dollars and are prepared in accordance with International Financial
Reporting Standards ("IFRS"), unless otherwise stated.
Financial Highlights (for the 2015 year compared to the
seventy-seven day comparative period ended March 31, 2014)
- Revenue was $4.4 million.
- Adjusted EBITDA was negative $0.3
million.
- Cash and cash equivalents were $2.8
million at year end.
- Raised gross proceeds of $27.8
million to fund acquisition program and growth
strategy.
Business Highlights
- Recruited a seasoned management team with deep healthcare and
capital markets experience.
- Acquired HSI, a California
based Emergency Medical Services ("EMS") billing services
provider.
Highlights Subsequent to Fiscal 2015
- Acquired Paragon Billing, LLC ("Paragon"), a leading provider
of behavioural health medical billing and electronic health records
("EHR").
- Completed qualifying transaction with the Company.
- Raised gross proceeds of CDN$10.0
million through a private placement.
- Syncordia commenced trading under the symbol "SYN" on the TSX
Venture Exchange July 8, 2015.
Management Commentary
"During our first year of operations,
we developed and began executing on our business plan to establish
Syncordia as a leading RCM company, targeting niche healthcare
providers," said Michael Franks,
Chief Executive Officer. "Thus far, we have raised more than
$40 million of capital, completed two
acquisitions of medical billing and RCM companies and laid the
foundation to support our development plans. We are focused on
executing our strategy, which comprises organic sales growth,
accretive acquisition opportunities, and the development of
Syncordia Cloud, our turn-key full service suite of cloud-based RCM
software modules. We look forward to reporting on our continued
success in the coming months", added Franks.
Full Year 2015 Financial Results
Revenue was
$4.4 million, split between air
transportation client billings of $3.8
million, ground transportation client billings of
$0.3 million and other revenue
streams of $0.3 million.
Gross margin was $2.9 million or
66% of revenues.
Adjusted EBITDA before Corporate costs was $1.3 million reflecting the five months of
operations of the RCM business segment.
Corporate costs were $1.6 million,
reflecting salaries, professional fees and other costs associated
with establishing the Company.
Adjusted EBITDA was negative $0.3
million.
Cash and cash equivalents increased to $2.8 million, reflecting $15.8 million of gross amounts raised through
equity and $12.0 million of gross
notes payable partially offset by $24.2
million used to purchase HSI. Other cash uses during 2015
totaled $0.8 million. Subsequent to
year end, we raised gross proceeds of CDN$10.0 million through a private placement.
Business Outlook
- We anticipate our RCM Business achieving $14.0 to $16.0 million of revenue and
$5.0 to $7.0 million of Adjusted
EBITDA on a twelve month run rate basis, prior to any further RCM
acquisitions.
- We anticipate that our Corporate costs will not exceed
$3.0 million on a similar twelve
month period, allowing us to support the continued growth of our
business.
- We anticipate continued investment in our Syncordia Cloud
business in line with the market demand for our cloud-based service
offering and the profitability of our business.
- We are actively engaged in negotiations with several
acquisition candidates and continue to build a promising pipeline
of targets.
Basis of Presentation
Syncordia Technologies and Healthcare
Solutions, Corp., formerly known as LL Capital Corp., reported its
fiscal 2015 financial results on May 15,
2015 prior to the qualifying transaction with Syncordia
Technologies and Healthcare Solutions, Inc. ("Syncordia Inc.").
Accordingly, the fiscal 2015 financial results of Syncordia Inc.
are not consolidated with that of Syncordia Technologies and
Healthcare Solutions, Corp. Beginning with our first quarter ended
June 30, 2015, financial information
will be reported on a consolidated basis.
Forward Looking Statements
Certain statements herein
may be "forward looking" statements that involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Syncordia or the industry
to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Forward looking statements involve significant risks
and uncertainties, should not be read as guarantees of future
performance or results, and will not necessarily be accurate
indications of whether or not such results will be achieved. A
number of factors could cause actual results to vary significantly
from the results discussed in the forward looking statements. These
forward looking statements reflect current assumptions and
expectations regarding future events and operating performance and
are made as of the date hereof and we assume no obligation, except
as required by law, to update any forward looking statements to
reflect new events or circumstances.
Cautionary Note Regarding Non-IFRS Measures
This press
release contains references to "EBITDA," "Adjusted EBITDA," and
"Adjusted EBITDA before Corporate costs."
Management defines EBITDA as Earnings before Interest, Taxes,
Depreciation and Amortization.
Management defines Adjusted EBITDA as Earnings before Interest,
Taxes, Depreciation, Amortization, Transaction Costs, Stock Based
Compensation and Cash based Share Compensation Arrangements.
Transaction costs include professional and other fees associated
with business transactions.
Management defines Adjusted EBITDA before Corporate costs as
Earnings before Interest, Taxes, Depreciation, Amortization,
Transaction Costs, Stock Based Compensation, Cash based Share
Compensation Arrangements and costs of our Corporate segment. This
metric is used to assess the performance of RCM and Syncordia cloud
segments.
Corporate costs include sales and marketing, general and
administrative and research and development, less amortization and
depreciation, stock-based compensation expense and stock
compensation indexed to our share price.
Management believes that EBITDA and Adjusted EBITDA are useful
supplemental measure of our operating performance. However, neither
EBITDA nor Adjusted EBITDA are recognized earnings measure under
IFRS and neither have a standardized meaning prescribed by IFRS.
Therefore, EBITDA and Adjusted EBITDA may not be comparable to
similar measures presented by other issuers. Neither EBITDA nor
Adjusted EBITDA should be construed as an alternative to net income
or loss.
About Syncordia Technologies and Healthcare
Solutions
We are a technology enhanced revenue cycle
management ("RCM") company focused on underserved niche segments of
the healthcare industry. Our growth strategy is to acquire RCM
businesses with and without software and, improve their
profitability by increasing revenues and operating efficiencies
using our software, and in time, commercializing the Syncordia
Cloud, our cloud-based software offering, to provide customer
demanded turn-key solutions from a single provider and to address
compelling RCM market opportunities.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
The following is a reconciliation of EBITDA with net loss and
comprehensive loss:
|
|
|
(in thousands of US
Dollars)
|
|
|
|
2015
|
2014
|
Net loss and
comprehensive loss
|
(2,895)
|
-
|
Amortization of
operating and other assets
|
1,082
|
-
|
Interest
expense
|
675
|
-
|
EBITDA
|
(1,138)
|
-
|
The following is a reconciliation of Adjusted EBITDA and Adjusted
EBITDA before corporate costs with net loss and comprehensive
loss:
|
|
|
(in thousands of US
Dollars)
|
|
|
|
2015
|
2014
|
Net loss and
comprehensive loss
|
(2,895)
|
-
|
Amortization of
operating and other assets
|
1,082
|
-
|
Interest
expense
|
675
|
-
|
Transaction
costs
|
822
|
-
|
Stock based
compensation
|
28
|
-
|
Adjusted
EBITDA
|
(288)
|
-
|
Corporate costs
(i)
|
1,577
|
-
|
Adjusted EBITDA
before Corporate costs
|
1,289
|
-
|
Notes:
(i) Non-IFRS
measure, corporate costs excludes stock based compensation and
amortization.
Syncordia Technologies and Healthcare Solutions,
Inc.
Consolidated Statements of Financial Position
As at March 31, 2015 and 2014
|
|
|
|
|
(expressed in US
dollars)
|
|
|
|
|
|
|
2015
$
|
|
2014
$
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
Cash and cash
equivalents
|
|
2,842,413
|
|
3
|
Accounts
receivable
|
|
1,931,076
|
|
-
|
Other
assets
|
|
145,304
|
|
-
|
|
|
|
|
|
|
|
4,918,793
|
|
3
|
|
|
|
|
|
Property and
equipment
|
|
168,418
|
|
-
|
|
|
|
|
|
Intangible
assets
|
|
16,134,626
|
|
-
|
|
|
|
|
|
Goodwill
|
|
5,836,719
|
|
-
|
|
|
|
|
|
|
|
27,058,556
|
|
3
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
Accounts payable and
accrued liabilities
|
|
1,135,379
|
|
-
|
Contingent
consideration payable
|
|
2,320,000
|
|
-
|
|
|
|
|
|
|
|
3,455,379
|
|
-
|
|
|
|
|
|
Notes
payable
|
|
10,483,989
|
|
-
|
|
|
|
|
|
|
|
13,939,368
|
|
-
|
|
|
|
|
|
Shareholders'
Equity
|
|
|
|
|
|
|
|
|
|
Capital
stock
|
|
14,387,095
|
|
3
|
|
|
|
|
|
Contributed
surplus
|
|
1,626,593
|
|
-
|
|
|
|
|
|
Deficit
|
|
(2,894,500)
|
|
-
|
|
|
|
|
|
|
|
13,119,188
|
|
3
|
|
|
|
|
|
|
|
27,058,556
|
|
3
|
Syncordia Technologies and Healthcare Solutions,
Inc.
Consolidated Statements of Loss and Comprehensive
Loss
For the year ended March 31, 2015
and the 77-day period ended March 31,
2014
|
|
|
|
|
(expressed in US
dollars)
|
|
|
|
|
|
|
Year
ended
March 31,
2015
$
|
|
77-day
period
ended
March 31,
2014
$
|
|
|
|
|
|
Revenue
|
|
4,391,812
|
|
-
|
|
|
|
|
|
Cost of
sales
|
|
1,507,654
|
|
-
|
|
|
|
|
|
Amortization of
operating assets
|
|
962,670
|
|
|
|
|
|
|
|
Gross
profit
|
|
1,921,488
|
|
-
|
|
|
|
|
|
Operating
expenses
|
|
3,199,442
|
|
-
|
|
|
|
|
|
Transaction
costs
|
|
821,805
|
|
|
|
|
|
|
|
Other
amortization
|
|
119,524
|
|
-
|
|
|
|
|
|
Loss before
interest expense
|
|
(2,219,283)
|
|
-
|
|
|
|
|
|
Interest
expense
|
|
675,217
|
|
-
|
|
|
|
|
|
Net loss and
comprehensive loss for the period
|
|
(2,894,500)
|
|
-
|
|
|
|
|
|
Net loss per
share
|
|
|
|
|
Basic and diluted
earnings per share
|
|
(0.33)
|
|
-
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
|
Basic
|
|
8,869,404
|
|
3,000,000
|
Diluted
|
|
8,893,782
|
|
3,000,000
|
Syncordia Technologies and Healthcare Solutions,
Inc.
Consolidated Statements of Cash Flows
For the year ended March 31, 2015
and the 77-day period ended March 31,
2014
|
|
|
|
|
(expressed in US
dollars)
|
|
|
|
|
|
|
Year
ended March 31, 2015 $
|
|
77-day period ended March 31, 2014 $
|
|
|
|
|
|
Cash provided by
(used in)
|
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
Net loss for the
period
|
|
(2,894,500)
|
|
-
|
Items not affecting
cash
|
|
|
|
|
|
Amortization
|
|
1,082,194
|
|
-
|
|
Non-cash interest on
notes payable
|
|
239,612
|
|
-
|
|
Share-based
compensation
|
|
27,524
|
|
-
|
Changes in non-cash
working capital items
|
|
|
|
|
|
Accounts
receivable
|
|
(878,900)
|
|
-
|
|
Other
assets
|
|
(51,769)
|
|
-
|
|
Accounts payable and
accrued liabilities
|
|
644,606
|
|
-
|
|
|
|
|
|
|
|
(1,831,233)
|
|
-
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
Purchase of property,
equipment and intangible assets
|
|
(102,056)
|
|
-
|
Acquisition of Health
Services Integration
|
|
(21,413,474)
|
|
-
|
|
|
|
|
|
|
|
(21,515,530)
|
|
-
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
Issuance of common
shares
|
|
-
|
|
3
|
Issuance of Class A
preferred shares
|
|
3,500,000
|
|
-
|
Issuance of Class B
preferred shares
|
|
12,281,442
|
|
-
|
Share issuance
costs
|
|
(867,032)
|
|
-
|
Proceeds from
long-term notes
|
|
12,000,000
|
|
-
|
Deferred financing
costs
|
|
(725,237)
|
|
-
|
|
|
|
|
|
|
|
26,189,173
|
|
3
|
|
|
|
|
|
Increase in cash
and cash equivalents during the period
|
|
2,842,410
|
|
3
|
|
|
|
|
|
Cash and cash
equivalents - Beginning of period
|
|
3
|
|
-
|
|
|
|
|
|
Cash and cash
equivalents - End of period
|
|
2,842,413
|
|
3
|
|
|
|
|
|
Cash interest
paid
|
|
435,605
|
|
-
|
|
|
|
|
|
SOURCE Syncordia Technologies and Healthcare Solutions,
Corp.